Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Marieke van Nieuwland, Edgar M Colin, Marloes Vermeer, Nils R L Wagenaar, Onno D Vijlbrief, Jordy K van Zandwijk, Riemer H J A Slart, Hendrik Koffijberg, Erik Groot Jebbink, Kornelis S M van der Geest, Elisabeth Brouwer, Dennis Boumans, Celina Alves
OBJECTIVES: This study directly compares diagnostic performance of Colour Duplex Ultrasound (CDUS), Fluor-18-deoxyglucose Positron Emission Tomography Computed Tomography (FDG-PET/CT) and Magnetic Resonance Imaging (MRI) in patients suspected of giant cell arteritis (GCA). METHODS: Patients with suspected GCA were included in a nested-case control pilot study. CDUS, whole body FDG-PET/CT and cranial MRI were performed within 5 working days after initial clinical evaluation...
April 10, 2024: Rheumatology
#2
JOURNAL ARTICLE
Antonis Fanouriakis, Myrto Kostopoulou, George Bertsias, Dimitrios T Boumpas
No abstract text is available yet for this article.
April 5, 2024: Annals of the Rheumatic Diseases
#3
JOURNAL ARTICLE
Kevin Windirsch, Suzana Jordan, Mike Oliver Becker, Cosimo Bruni, Rucsandra Dobrota, Muriel Elhai, Ion-Alexandru Garaiman, Carmen-Marina Mihai, Michele Iudici, Paul Hasler, Camillo Ribi, Britta Maurer, Armando Gabrielli, Anna-Maria Hoffmann-Vold, Oliver Distler
OBJECTIVES: Systemic sclerosis is a chronic autoimmune connective tissue disease leading to microvascular and fibrotic manifestations in multiple organs. Several treatment options and recommendations from different European countries are available. In this study, for which the ambit is Switzerland specifically, we aim to describe the treatment patterns of systemic sclerosis patients with fibrotic manifestations. METHODS: Systemic sclerosis patients were selected from six Swiss tertiary centres recorded in the multicentre, prospective European Scleroderma Trials and Research (EUSTAR) registry...
February 6, 2024: Swiss Medical Weekly
#4
JOURNAL ARTICLE
Bernhard Hellmich, David Jayne
No abstract text is available yet for this article.
April 3, 2024: Annals of the Rheumatic Diseases
#5
JOURNAL ARTICLE
Daniel G Fernández-Ávila, Wilson Bautista-Molano, María Lorena Brance, María Gabriela Ávila Pedretti, Rubén Burgos Vargas, José Francisco Díaz Coto, Luis Arturo Gutiérrez, Marwin Gutiérrez, Enrique Giraldo Ho, Sebastián Eduardo Ibáñez Vodnizza, Edwin Jáuregui, Vanessa Ocampo, Penélope Esther Palominos, Daniel Ruben Palleiro Rivero, Guillermo Andrés Quiceno, Fernando Andrés Sommerfleck, Luis Enrique Vega Espinoza, Oscar Vega Hinojosa, Claudia Vera Barrezueta, Inés Corbacho, Vanesa Laura Cosentino, Annelise Goecke Sariego, Gustavo Gomes Resende, Lina María Saldarriaga-Rivera, Cesar Francisco Pacheco Tena, Gustavo Citera, Carlos Lozada, Roberto Ranza, Percival D Sampaio-Barros, Emilce Schneeberger, Enrique R Soriano
OBJECTIVE: Psoriatic arthritis (PsA) is chronic disease that compromise multiple domains, and might be associated with progressive joint damage, increased mortality, functional limitation, and considerably impaired quality of life. Our objective is to generate evidence-based recommendations on the management of PsA in PANLAR countries. METHODS: We used the Grading of Recommendations, Assessment, Development and Evaluation GRADEADOLOPMENT approach to adapt the 2019 recommendations of the European League Against Rheumatism (EULAR)...
April 1, 2024: Journal of Rheumatology
#6
JOURNAL ARTICLE
Alwin Sebastian, Kornelis S M van der Geest, Alessandro Tomelleri, Pierluigi Macchioni, Giulia Klinowski, Carlo Salvarani, Diana Prieto-Peña, Edoardo Conticini, Muhammad Khurshid, Lorenzo Dagna, Elisabeth Brouwer, Bhaskar Dasgupta
BACKGROUND: Giant cell arteritis is a critically ischaemic disease with protean manifestations that require urgent diagnosis and treatment. European Alliance of Associations for Rheumatology (EULAR) recommendations advocate ultrasonography as the first investigation for suspected giant cell arteritis. We developed a prediction tool that sequentially combines clinical assessment, as determined by the Southend Giant Cell Arteritis Probability Score (SGCAPS), with results of quantitative ultrasonography...
March 27, 2024: Lancet Rheumatology
#7
JOURNAL ARTICLE
Sharon Cowley, Patricia Harkins, Colm Kirby, Richard Conway, David J Kane
There is a growing appreciation that both giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are closely interrelated conditions that have significant overlap in aetiology, clinical characteristics and treatment regimens. Subclinical GCA in PMR is becoming increasingly recognised, and there is evolving evidence that this may be a more aggressive disease phenotype than PMR. Ultrasound (US) lends itself well as a screening tool for GCA in PMR; it is inexpensive, non-invasive, widely available, lacks ionising radiation, may be performed at the bedside and is recommended by EULAR as a first-line investigation for suspected GCA...
March 29, 2024: Annals of the Rheumatic Diseases
#8
JOURNAL ARTICLE
Andreas Kerschbaumer, Josef S Smolen, Ricardo J O Ferreira, Heidi Bertheussen, Xenofon Baraliakos, Daniel Aletaha, Dennis G McGonagle, Désirée van der Heijde, Iain B McInnes, Bente Appel Esbensen, Kevin L Winthrop, Wolf-Henning Boehncke, Jan W Schoones, Laure Gossec
OBJECTIVES: To obtain an overview of recent evidence on efficacy and safety of pharmacological treatments in psoriatic arthritis (PsA). METHODS: This systematic literature research (SLR) investigated the efficacy and safety of conventional synthetic (cs), biological (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs) in patients with PsA. A systematic database search using Medline, EMBASE, Cochrane CENTRAL was conducted to identify relevant articles published since the previous update in 2019 until 28 December 2022...
March 19, 2024: Annals of the Rheumatic Diseases
#9
JOURNAL ARTICLE
Marius Henriksen
No abstract text is available yet for this article.
March 18, 2024: Nature Reviews. Rheumatology
#10
JOURNAL ARTICLE
Laure Gossec, Andreas Kerschbaumer, Ricardo J O Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf-Henning Boehncke, Bente Appel Esbensen, Iain B McInnes, Dennis McGonagle, Kevin L Winthrop, Andra Balanescu, Peter V Balint, Gerd R Burmester, Juan D Cañete, Pascal Claudepierre, Lihi Eder, Merete Lund Hetland, Annamaria Iagnocco, Lars Erik Kristensen, Rik Lories, Rubén Queiro, Daniele Mauro, Helena Marzo-Ortega, Philip J Mease, Peter Nash, Wendy Wagenaar, Laura Savage, Georg Schett, Stephanie J W Shoop-Worrall, Yoshiya Tanaka, Filip E Van den Bosch, Annette van der Helm-van Mil, Alen Zabotti, Désirée van der Heijde, Josef S Smolen
OBJECTIVE: New modes of action and more data on the efficacy and safety of existing drugs in psoriatic arthritis (PsA) required an update of the EULAR 2019 recommendations for the pharmacological treatment of PsA. METHODS: Following EULAR standardised operating procedures, the process included a systematic literature review and a consensus meeting of 36 international experts in April 2023. Levels of evidence and grades of recommendations were determined. RESULTS: The updated recommendations comprise 7 overarching principles and 11 recommendations, and provide a treatment strategy for pharmacological therapies...
March 18, 2024: Annals of the Rheumatic Diseases
#11
JOURNAL ARTICLE
Nadine Zehrfeld, Torsten Witte, Diana Ernst
Sjögren's syndrome (SjS) is the most common connective tissue disease with a prevalence of 1:200. Predominantly affecting women, SjS is associated with destruction of the exocrine glands, leading to xerophthalmia and xerostomia. In over 50% of patients, there are also extraglandular manifestations, leading to multiple organ manifestations including polyneuropathies and interstitial lung disease as well as symptoms such as fatigue and arthralgia. Diagnostic procedures include biomarkers, in particular anti-SS-A/Ro antibodies, histology of salivary glands, and salivary gland sonography...
March 18, 2024: Zeitschrift Für Rheumatologie
#12
JOURNAL ARTICLE
Aude Belbézier, Thi Thu Thuy Nguyen, Mélanie Arnaud, Bruna Ducotterd, Marie Vangout, Alban Deroux, Catherine Mansard, Françoise Sarrot-Reynauld, Laurence Bouillet
Sjögren's syndrome (SS) is a systemic autoimmune pathology manifested mainly by a dry syndrome, intense asthenia and arthromyalgia. Systemic manifestations may also occur. Since 2019, immunosuppressant agents (IS) or biotherapies are recommended only for patients with systemic involvement. However, before 2019, in some cases, paucisymptomatic patients had been treated with IS/biotherapies, often off-label. Objective : We propose to evaluate the benefit and safety of using IS/biotherapy in patients with SS without systemic involvement...
June 2024: Journal of translational autoimmunity
#13
JOURNAL ARTICLE
Céline Schweri, Michele Iudici
Early diagnosis and prompt initiation of treatment are crucial to avoid severe complications in giant cell arteritis (GCA). The European Alliance of Associations for Rheumatology (EULAR) recommendations for the use of imaging in large vessel vasculitis have helped better define the role of different techniques for diagnosing and monitoring the disease. Regarding the treatment, corticosteroids remain the standard, and tocilizumab is the preferred corticosteroid-sparing treatment. New corticosteroid-sparing treatments and "ultra-light" corticosteroid usage regimens are also under study and could represent valid therapeutic alternatives in the future...
March 13, 2024: Revue Médicale Suisse
#14
JOURNAL ARTICLE
Christel Madelaine-Bonjour, Alice Grosjean
In Switzerland, patient education in rheumatology faces challenges, despite national advances following the development of the concept of self-management support by the Federal Office of Health. Yet it is a fundamental pillar of rheumatic disease management, meeting the needs of both patients and healthcare professionals. It helps to improve the overall quality of care and is recommended by the European Alliance of Associations for Rheumatology (EULAR). Training in PE needs to be strengthened, as does the evaluation of programmes, which must take account of the specific nature of rheumatic diseases...
March 13, 2024: Revue Médicale Suisse
#15
REVIEW
Ewa Pędzich, Adrian Bednarek, Julita Młynarska, Emilia Włoszek, Dominika Klimczak-Tomaniak, Karolina Gumiężna, Adam Piasecki, Adam Rdzanek, Grażyna Sygitowicz, Marcin Grabowski, Mariusz Tomaniak
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a complex multifactorial etiology that develops as a result of autoimmune processes, leading to widespread inflammation and malfunction of multiple tissues and organs, and, as a consequence, triggers arterial hypertension, conduction disorders, valvular heart disease, pulmonary hypertension (PH), and venous thromboembolism events (VTE), contributing to increased mortality. Moreover, autoimmune abnormalities can accelerate atherogenesis and lead to many SLE manifestations, including coronary artery disease (CAD) and cerebrovascular events...
March 12, 2024: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
#16
REVIEW
Bimbi Gray, Alison Gibbs, Jocelyn L Bowden, Jillian P Eyles, Sandra Grace, Kim Bennell, Rinie Geenen, Sharon Kolasinski, Christian Barton, Philip G Conaghan, Timothy McAlindon, Olivier Bruyere, Quentin Géczy, David J Hunter
OBJECTIVE: Clinical Practice Guidelines (CPGs) aim to support management of hip and knee osteoarthritis (OA), but recommendations are often conflicting and implementation is poor, contributing to evidence-to-practice gaps. This systematic review investigated the contextual and methodological factors contributing to conflicting recommendations for hip and knee OA. METHOD: Our systematic review appraised CPGs for managing hip and knee OA in adults ≥18 years (PROSPERO CRD42021276635)...
March 5, 2024: Osteoarthritis and Cartilage
#17
JOURNAL ARTICLE
Beatriz Frade-Sosa, Tarek Carlos Salman-Monte, Javier Narváez, Irene Peralta, Sebastian Sandoval, Berta Magallares, Sergi Heredia, Nuria Sapena, Anne Riveros-Frutos, Alejandro Olivé, Hector Corominas, Josefina Cortés-Hernández, José A Gómez-Puerta
BACKGROUND: In 2017, belimumab (BEL) was approved in subcutaneous (SQ) administration. The effectiveness after switching from intravenous (IV) to SQ and patient satisfaction in daily clinical practice has not been studied. During the pandemic, patient follow-up and treatment were significantly affected, and some patients need a change from IV to SQ. Our aim was to evaluate daily clinical practice satisfaction to SQ BEL therapy in patients previously treated IV BEL. We hypothesized that SQ BEL in SLE patients previously treated with IV BEL was similar in effectiveness and conferred higher satisfaction...
March 6, 2024: Lupus
#18
JOURNAL ARTICLE
Tianmin Tang, Hongyu Jin, Yujia Yang
BACKGROUND: The European League Against Rheumatism-Outcomes Measures in Rheumatology (EULAR-OMERACT) recommend only scanning dorsal spaces for scoring ultrasound-detected hand synovitis. This study evaluated the efficiency of the combined scoring system only depending on dorsal joint spaces synovitis in diagnosing and evaluating ultrasound-detected hand synovitis. METHODS: The data of 56 patients who underwent hand joint ultrasonography exams in the Ultrasound Department of West China Hospital, Sichuan University were prospectively collected...
February 1, 2024: Quantitative Imaging in Medicine and Surgery
#19
JOURNAL ARTICLE
Julie Katrine Karstensen, Ann Bremander, Jeanette Reffstrup Christensen, Jette Primdahl
BACKGROUND: In accordance with the EULAR recommendations, the Danish Hospital for Rheumatic Diseases have systematically invited patients with rheumatoid arthritis (RA) to cardiovascular (CV) risk assessment since 2011. Patients with high risk are invited to a follow-up screening after one year. To optimize the screening and tailor it to individual needs, information about who accepts vs. declines follow-up is needed. Thus, the aim of this study was to explore participation in systematic CV risk assessment among patients with RA...
February 22, 2024: BMC rheumatology
#20
JOURNAL ARTICLE
Kader Cetin Gedik, Zehra Serap Arici, Ovgu Kul Cinar, Facundo Garcia-Bournissen, Micol Romano, Erkan Demirkaya
Systemic autoinflammatory diseases (SAIDs) are a group of rare genetic and nongenetic immune dysregulatory disorders associated with high morbidity and mortality if left untreated. Therefore, early diagnosis and initiation of targeted treatment is vital in SAID patients to control the disease activity and prevent long-term immune-mediated damage. A specific group of genetically defined SAIDs is associated with increased inflammasome-mediated production of active interleukin (IL)-1. Even though progress in immunobiology and genetics has brought forth diagnostic tools and novel treatments that have been described in the literature extensively, many challenges remain in the clinical setting...
February 20, 2024: Paediatric Drugs
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
